Pharma channel feed – Endpoints News

Pharma channel feed

Novartis, UCSF researchers urge FDA to clean up its messy adverse events database

8 years ago

SteadyMed shares slammed as FDA tosses its NDA for PAH drug-device

8 years ago

Daiichi Sankyo punts $650M collaboration pact as Charleston Labs preps a comeback attempt on spurned pain drug

8 years ago

FDA ushers in a new era in cancer treatment with 'historic' CAR-T approval for Novartis

8 years ago

BioMarin says the FDA game clock now ticking on their blockbuster hopeful pegvaliase

8 years ago

In stunning about-face, FDA invites Eli Lilly to quickly refile blockbuster hopeful baricitinib

8 years ago

Medicines Co scores FDA OK for new antibiotic, now up on the auction block

8 years ago

A nonprofit group’s Chagas drug beat out Martin Shkreli's old rival to FDA OK, valuable PRV

8 years ago

Celgene antes up $195M more to stay close to Forma, adding neurodegeneration focus

8 years ago

Seven years in the making, Seattle Genetics picks up early option on Genmab's ADC effort

8 years ago

FDA derails Acorda's marketing pitch, creating a crisis as flagship drug founders

8 years ago

Jazz gambles $175M on a triple-pronged armed antibody pact with ImmunoGen

8 years ago

AstraZeneca auctions off rights to another pipeline drug as Takeda grabs $400M Parkinson's deal

8 years ago

Aveo takes a big step forward as comeback plan delivers EU OK for tivo

8 years ago

After a long, painful revamp, Merck KGaA scores key OK for once-defunct MS drug cladribine

8 years ago

Novartis returns to the discount aisle, buys Xoma's failed PhIII drug for $31M

8 years ago

Pfizer has found a stylish new home for its HQ in Manhattan — report

8 years ago

After a long clinical odyssey, the FDA tapped this PhIII anti-CCR4 as a ‘breakthrough’ lymphoma drug

8 years ago

Adamas wins its first FDA OK, setting up market launch for a reformulated Parkinson’s drug

8 years ago

EMA and FDA will now share trade secrets, allowing both regulators to act on each other's inspection reports

8 years ago

Can Amgen beat down payer resistance to Repatha with its own cost analysis?

8 years ago

New docs spotlight the FDA’s failed attempt to get Sarepta’s flawed Duchenne study retracted

8 years ago

FDA throws up another roadblock to Cardiome, 9 years after rejecting its drug

8 years ago

Building up its I/O ops, CRISPR Therapeutics allies with Marcela Maus at Mass General

8 years ago

First page Previous page 315 316 317318319 320 321 Next page Last page